- Home
- BTOG vs WINT Comparison
BTOG vs WINT Comparison
Compare BTOG & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTOG
- WINT
- Stock Information
- Founded
- BTOG 2018
- WINT 1992
- Country
- BTOG Singapore
- WINT United States
- Employees
- BTOG N/A
- WINT N/A
- Industry
- BTOG Finance: Consumer Services
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTOG Finance
- WINT Health Care
- Exchange
- BTOG Nasdaq
- WINT Nasdaq
- Market Cap
- BTOG 1.2M
- WINT 996.6K
- IPO Year
- BTOG 2019
- WINT 1995
- Fundamental
- Price
- BTOG $0.15
- WINT $1.21
- Analyst Decision
- BTOG
- WINT Hold
- Analyst Count
- BTOG 0
- WINT 1
- Target Price
- BTOG N/A
- WINT $350.00
- AVG Volume (30 Days)
- BTOG 34.3M
- WINT 347.9K
- Earning Date
- BTOG 01-01-0001
- WINT 05-06-2025
- Dividend Yield
- BTOG N/A
- WINT N/A
- EPS Growth
- BTOG N/A
- WINT N/A
- EPS
- BTOG N/A
- WINT N/A
- Revenue
- BTOG N/A
- WINT N/A
- Revenue This Year
- BTOG N/A
- WINT N/A
- Revenue Next Year
- BTOG N/A
- WINT N/A
- P/E Ratio
- BTOG N/A
- WINT N/A
- Revenue Growth
- BTOG N/A
- WINT N/A
- 52 Week Low
- BTOG $0.12
- WINT $1.01
- 52 Week High
- BTOG $5.73
- WINT $737.50
- Technical
- Relative Strength Index (RSI)
- BTOG 42.51
- WINT 35.07
- Support Level
- BTOG $0.14
- WINT $1.01
- Resistance Level
- BTOG $0.19
- WINT $1.19
- Average True Range (ATR)
- BTOG 0.03
- WINT 0.14
- MACD
- BTOG 0.01
- WINT 0.12
- Stochastic Oscillator
- BTOG 28.79
- WINT 41.67
About BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.